# Cerulean Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cerulean-pharma

- Industry: Pharmaceuticals
- Headquarters: Waltham, US
- Website: www.ceruleanrx.com
- Total disclosed funding: $80M
- Latest round: Series D (Nov 30, 2012)
- Investors on record: 7

## About

Cerulean Pharma Inc. is a biopharmaceutical company focused on developing innovative cancer therapies utilizing its proprietary technology platform to deliver therapeutics efficiently and effectively.Established in 2006 and headquartered in Waltham, US, Cerulean Pharma Inc. specializes in biopharmaceuticals targeting cancer treatment. The company underwent a strategic shift through its merger with Daré Bioscience, enhancing its clinical product offerings. The CEO, Sabrina Johnson, leads the company, which successfully raised USD 1.50 mn in its latest funding round in April 2014, bringing the total amount raised to USD 1.50 mn. The company has completed 15 deals to date, with its most recent deal being a trade sale.Cerulean Pharma Inc. develops advanced cancer therapies through its proprietary drug delivery platform, focusing on improving the efficacy of therapeutic agents. Its innovative approach aims to enhance patient outcomes by delivering drugs directly to tumors while minimizing side effects, thus addressing critical needs in oncology.In its most recent financial year, Cerulean Pharma Inc. reported a revenue of USD 9,784 mn, alongside an EBITDA of USD -23,409,160 in 2024.Cerulean Pharma plans to expand its product pipeline with new oncology therapies aimed for launch in the upcoming years. The company is also targeting expansion into additional international markets to broaden its reach and accessibility. Recent funding from the trade sale will be utilized to support these development initiatives and enhance operational capabilities.

## Funding rounds

- Series D, Nov 30, 2012, $13M — Polaris Partners, Lilly Ventures, Venrock, CVF Capital Partners, Bessemer Venture Partners, Lux Capital
- Series D, Dec 15, 2011, $15M — Polaris Partners, Lilly Ventures, Venrock, CVF Capital Partners, Bessemer Venture Partners, Lux Capital
- Series C, Jun 15, 2011, $3.2M — Polaris Partners, Bessemer Venture Partners
- Series C, Nov 15, 2010, $17M — Polaris Partners, Lilly Ventures, Venrock, Bessemer Venture Partners, Lux Capital
- Series B, Jul 28, 2009, $10M — Polaris Partners, Venrock, Bessemer Venture Partners, Lux Capital
- Series B, Jan 3, 2008, $8.1M — Polaris Partners, Venrock, Alexandria Venture Investments, Bessemer Venture Partners, Lux Capital
- Series A, May 23, 2007, $12M — Polaris Partners, Venrock, Lux Capital
- Seed, Dec 1, 2006, $2M — Polaris Partners

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Seed, Series A, Series B, Series C, Series D
- Venrock (https://capitalatlas.ai/funds/venrock) — Series A, Series B, Series C, Series D
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series A, Series B, Series C, Series D
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series B, Series C, Series D
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series C, Series D
- CVF Capital Partners — Series D